Poseida Therapeutics, Inc. (PSTX) NASDAQ
9.50
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Poseida Therapeutics, Inc.
Address
9390 Towne Centre Drive
San Diego, CA 92121
United States of America (the)
Phone
858 779 3100
Website
Sector
Healthcare
Industry
Biotechnology
Employees
350
First IPO Date
July 10, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Kristin Yarema | President, Chief Executive Officer & Director | 711,986 | 1971 |
| Harry J. Leonhardt | General Counsel, Chief Compliance Officer & Corporate Secretary | 630,233 | 1957 |
| Mark J. Gergen | Executive Chairman of the Board | 961,797 | 1963 |
| Jeffrey W. Winkelman | Senior Vice President & Chief Patent Counsel | 0 | N/A |
| Alexander Chapman | Senior Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Loren Wagner | Chief Operations Officer | 0 | N/A |
| Johanna Mylet | Chief Financial Officer | 0 | 1988 |
| Devon J. Shedlock | Chief Scientific Officer of Cell Therapy | 0 | N/A |
| Lisa Portale | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Karen Basbaum | Senior Vice President of Business Development | 0 | N/A |
| Kristin Martin | Chief People & Administration Officer | 0 | N/A |
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
